From GlobeNewswire: 2025-06-18 06:04:00

The Critical Limb Ischemia Treatment Market is projected to reach USD 10.02 Bn by 2032, with a CAGR of 8.8% from 2025. Factors like the global geriatric population and rising peripheral artery disease cases are driving market growth. North America is expected to hold a significant market share, with Asia Pacific experiencing the fastest growth.

Antihypertensive agents are expected to dominate the market by generating around USD 1.69 Bn in 2025. Parenteral administration is likely to hold over three-fifths of the market share, while hospitals are anticipated to account for over 2/5 of the market by 2025. The rise in diabetes and peripheral artery disease cases is fueling market growth, with more than 202 million adults worldwide affected by PAD.

The market outlook is promising due to the increasing prevalence of PAD, but high treatment costs may limit growth. Improved diagnostic rates, driven by advanced technologies like duplex ultrasound and MRA, are expected to create new growth opportunities. Artificial intelligence is revolutionizing CLI treatment by enhancing diagnostic speed and treatment precision.

Industry players are focusing on non-invasive and pharmacological therapies to drive market growth. Advancements in therapies like stem cell and gene therapy, along with personalized medicine, are expected to improve clinical outcomes. The trend towards combination therapies is also expected to boost sales growth in the market.

Recent developments include the FDA fast-tracking novel CLI therapies and breakthrough clinical trial results for gene therapy. AI integration in diagnosis and prognosis is also a key trend. Major companies in the market include AstraZeneca, Medtronic, and Abbott Laboratories. Key developments include Penumbra’s clinical study and Abbott’s FDA-approved dissolving stent.

Market segmentation includes drugs like antihypertensive agents and antithrombotic agents, various routes of administration, end users like hospitals and specialty clinics, and regions like North America and Asia Pacific. High treatment costs remain a challenge, but the rising prevalence of CLI and advancements in diagnostic technologies are creating lucrative growth opportunities.



Read more at GlobeNewswire: Critical Limb Ischemia Treatment Market to Reach USD 10.02